Reductive C(sp<sup>2</sup>)–C(sp<sup>3</sup>) Coupling Protocol to Enable Linker Exploration of Cereblon E3-Ligase BRD4 Proteolysis-Targeting Chimeras

Heterobifunctional degraders (also known as proteolysis-targeting chimeras or PROTACs) have emerged in drug discovery as an alternative therapeutic modality for targeting disease-causing proteins that are challenging to modulate with standard protein inhibitors. Almost all current PROTACs under clinical studies use the E3 ligase cereblon (CRBN) to hijack the ubiquitin-proteasome system. In this study, we used high-throughput experimentation to identify new conditions to access carbon-carbon bonds on our CRBN warheads. These efforts led to the discovery that alkyl-connected CRBN binders demonstrate improved cell permeability and reduced neosubstrate activity when compared with their amide counterparts. To further demonstrate the value of this protocol and the resulting alkyl connection point, these conditions were utilized as a final synthetic step to produce a heterobifunctional BRD4 degrader with an improved CRBN neosubstrate selectivity profile compared to its amide counterpart.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2025-05-09
DOI
https://doi.org/10.1021/acs.jmedchem.4c03157
Citations
6
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
4.84
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Reductive C(sp2)–C(sp3) Coupling Protocol to Enable Linker Exploration of Cereblon E3-Ligase BRD4 Proteolysis-Targeting Chimeras

Amanda Del Rosario, Kaitlyn Lovato, Jennifer D. Venable, Harris Bell‐Temin et al.
6 citations
Journal of Medicinal Chemistry
Protein Degradation and Inhibitors
4.84
article

Reductive C(sp2)–C(sp3) Coupling Protocol to Enable Linker Exploration of Cereblon E3-Ligase BRD4 Proteolysis-Targeting Chimeras

Amanda Del Rosario, Kaitlyn Lovato, Jennifer D. Venable, Harris Bell‐Temin, Ji‐Hoon Cho, Nadeem A. Vellore, Seth P. Miller, Charu Chaudhry, Christine F. Gelin, Jean-François Brazeau, Taylor M. Courtney, Lu Zhu, Danielle Loskot
article en
6 citations

Abstract

Heterobifunctional degraders (also known as proteolysis-targeting chimeras or PROTACs) have emerged in drug discovery as an alternative therapeutic modality for targeting disease-causing proteins that are challenging to modulate with standard protein inhibitors. Almost all current PROTACs under clinical studies use the E3 ligase cereblon (CRBN) to hijack the ubiquitin-proteasome system. In this study, we used high-throughput experimentation to identify new conditions to access carbon-carbon bonds on our CRBN warheads. These efforts led to the discovery that alkyl-connected CRBN binders demonstrate improved cell permeability and reduced neosubstrate activity when compared with their amide counterparts. To further demonstrate the value of this protocol and the resulting alkyl connection point, these conditions were utilized as a final synthetic step to produce a heterobifunctional BRD4 degrader with an improved CRBN neosubstrate selectivity profile compared to its amide counterpart.

Journal of Medicinal ChemistryVol. 68(10)
Johnson & Johnson (United States) (US), Johnson & Johnson (Israel) (IL), Molecular Discovery (United Kingdom) (GB)
Zero hunger
Openalex Percentile: Top 5%
Protein Degradation and Inhibitors
4.84
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.